Brief Report: Retrospective Case Series of Oxcarbazepine for Irritability/Agitation Symptoms in Autism Spectrum Disorder / Jessica F. DOUGLAS in Journal of Autism and Developmental Disorders, 43-5 (May 2013)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 43-5 (May 2013) . - p.1243-1247 Titre : Brief Report: Retrospective Case Series of Oxcarbazepine for Irritability/Agitation Symptoms in Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Jessica F. DOUGLAS, Auteur ; Kevin B. SANDERS, Auteur ; M. Hannah BENNEYWORTH, Auteur ; Jessica L. SMITH, Auteur ; Virginia M. DEJEAN, Auteur ; Susan G. MCGREW, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur Article en page(s) : p.1243-1247 Langues : Anglais (eng) Mots-clés : Antiepileptic  Anticonvulsant  Mood stabilizer  Sodium channel  Pervasive developmental disorder Index. décimale : PER Périodiques Résumé : We examined response to oxcarbazepine prescribed for irritability/agitation symptoms in a retrospective case series of 30 patients with Autism Spectrum Disorder (ASD). The average patient was 12.0 years old (range 5–21) and taking two other psychotropic medications (range 0–4). Fourteen patients (47 %) had a clinical global impression of improvement score of ‘much improved’ during treatment. Ten patients (33 %) showed an improvement on their clinical global impression of severity score. Seven patients (23 %) had a clinically significant adverse event or side effect leading to oxcarbazepine discontinuation. Without a placebo group, it is not possible to evaluate whether oxcarbazepine provides benefit for irritability/agitation symptoms in ASD. The high rate of adverse events suggests its use should be accompanied by caution. En ligne : http://dx.doi.org/10.1007/s10803-012-1661-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=195 [article] Brief Report: Retrospective Case Series of Oxcarbazepine for Irritability/Agitation Symptoms in Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Jessica F. DOUGLAS, Auteur ; Kevin B. SANDERS, Auteur ; M. Hannah BENNEYWORTH, Auteur ; Jessica L. SMITH, Auteur ; Virginia M. DEJEAN, Auteur ; Susan G. MCGREW, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur . - p.1243-1247. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 43-5 (May 2013) . - p.1243-1247 Mots-clés : Antiepileptic  Anticonvulsant  Mood stabilizer  Sodium channel  Pervasive developmental disorder Index. décimale : PER Périodiques Résumé : We examined response to oxcarbazepine prescribed for irritability/agitation symptoms in a retrospective case series of 30 patients with Autism Spectrum Disorder (ASD). The average patient was 12.0 years old (range 5–21) and taking two other psychotropic medications (range 0–4). Fourteen patients (47 %) had a clinical global impression of improvement score of ‘much improved’ during treatment. Ten patients (33 %) showed an improvement on their clinical global impression of severity score. Seven patients (23 %) had a clinically significant adverse event or side effect leading to oxcarbazepine discontinuation. Without a placebo group, it is not possible to evaluate whether oxcarbazepine provides benefit for irritability/agitation symptoms in ASD. The high rate of adverse events suggests its use should be accompanied by caution. En ligne : http://dx.doi.org/10.1007/s10803-012-1661-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=195

Diagnostic Yield of Chromosomal Microarray Analysis in an Autism Primary Care Practice: Which Guidelines to Implement? / Susan G. MCGREW in Journal of Autism and Developmental Disorders, 42-8 (August 2012)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 42-8 (August 2012) . - p.1582-1591 Titre : Diagnostic Yield of Chromosomal Microarray Analysis in an Autism Primary Care Practice: Which Guidelines to Implement? Type de document : Texte imprimé et/ou numérique Auteurs : Susan G. MCGREW, Auteur ; Brittany R. PETERS, Auteur ; Julie CRITTENDON, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur Année de publication : 2012 Article en page(s) : p.1582-1591 Langues : Anglais (eng) Mots-clés : Genetic testing guidelines  Chromosomal microarray  Karyotype  Dysmorphology Index. décimale : PER Périodiques Résumé : Genetic testing is recommended for patients with ASD; however specific recommendations vary by specialty. American Academy of Pediatrics and American Academy of Neurology guidelines recommend G-banded karyotype and Fragile X DNA. The American College of Medical Genetics recommends Chromosomal Microarray Analysis (CMA). We determined the yield of CMA (N = 85), karyotype (N = 119), and fragile X (N = 174) testing in a primary pediatrics autism practice. We found twenty (24%) patients with abnormal CMA results (eight were clinically significant), three abnormal karyotypes and one Fragile X syndrome. There was no relationship between CMA result and cognitive level, seizures, dysmorphology, congenital malformations or behavior. We conclude that CMA should be the clinical standard in all specialties for first tier genetic testing in ASD. En ligne : http://dx.doi.org/10.1007/s10803-011-1398-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=178 [article] Diagnostic Yield of Chromosomal Microarray Analysis in an Autism Primary Care Practice: Which Guidelines to Implement? [Texte imprimé et/ou numérique] / Susan G. MCGREW, Auteur ; Brittany R. PETERS, Auteur ; Julie CRITTENDON, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur . - 2012 . - p.1582-1591. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 42-8 (August 2012) . - p.1582-1591 Mots-clés : Genetic testing guidelines  Chromosomal microarray  Karyotype  Dysmorphology Index. décimale : PER Périodiques Résumé : Genetic testing is recommended for patients with ASD; however specific recommendations vary by specialty. American Academy of Pediatrics and American Academy of Neurology guidelines recommend G-banded karyotype and Fragile X DNA. The American College of Medical Genetics recommends Chromosomal Microarray Analysis (CMA). We determined the yield of CMA (N = 85), karyotype (N = 119), and fragile X (N = 174) testing in a primary pediatrics autism practice. We found twenty (24%) patients with abnormal CMA results (eight were clinically significant), three abnormal karyotypes and one Fragile X syndrome. There was no relationship between CMA result and cognitive level, seizures, dysmorphology, congenital malformations or behavior. We conclude that CMA should be the clinical standard in all specialties for first tier genetic testing in ASD. En ligne : http://dx.doi.org/10.1007/s10803-011-1398-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=178

Erratum to: Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes / Beth A. MALOW in Journal of Autism and Developmental Disorders, 42-8 (August 2012)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 42-8 (August 2012) . - p.1738 Titre : Erratum to: Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes Type de document : Texte imprimé et/ou numérique Auteurs : Beth A. MALOW, Auteur ; Karen W. ADKINS, Auteur ; Susan G. MCGREW, Auteur ; Lily WANG, Auteur ; Suzanne E. GOLDMAN, Auteur ; Diane FAWKES, Auteur ; Courtney BURNETTE, Auteur Année de publication : 2012 Article en page(s) : p.1738 Langues : Anglais (eng) Mots-clés : Melatonin  Insomnia  Actigraphy  Clinical trial  Children’s sleep habits questionnaire  Child behavior checklist  Autism diagnostic observation schedule Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1007/s10803-012-1507-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=178 [article] Erratum to: Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes [Texte imprimé et/ou numérique] / Beth A. MALOW, Auteur ; Karen W. ADKINS, Auteur ; Susan G. MCGREW, Auteur ; Lily WANG, Auteur ; Suzanne E. GOLDMAN, Auteur ; Diane FAWKES, Auteur ; Courtney BURNETTE, Auteur . - 2012 . - p.1738. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 42-8 (August 2012) . - p.1738 Mots-clés : Melatonin  Insomnia  Actigraphy  Clinical trial  Children’s sleep habits questionnaire  Child behavior checklist  Autism diagnostic observation schedule Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1007/s10803-012-1507-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=178

Gastrointestinal Dysfunction in Autism: Parental Report, Clinical Evaluation, and Associated Factors / Phillip GORRINDO in Autism Research, 5-2 (April 2012)  

Public ISBD [article]  inAutism Research > 5-2 (April 2012) . - p.101-108 Titre : Gastrointestinal Dysfunction in Autism: Parental Report, Clinical Evaluation, and Associated Factors Type de document : Texte imprimé et/ou numérique Auteurs : Phillip GORRINDO, Auteur ; Dean C. WILLIAMS, Auteur ; Evon B. LEE, Auteur ; Lynn S. WALKER, Auteur ; Susan G. MCGREW, Auteur ; Pat LEVITT, Auteur Année de publication : 2012 Article en page(s) : p.101-108 Langues : Anglais (eng) Mots-clés : autism  constipation  diet  functional gastrointestinal disorders  nonverbal communication  social behavior Index. décimale : PER Périodiques Résumé : The objectives of this study were to characterize gastrointestinal dysfunction (GID) in autism spectrum disorder (ASD), to examine parental reports of GID relative to evaluations by pediatric gastroenterologists, and to explore factors associated with GID in ASD. One hundred twenty-one children were recruited into three groups: co-occurring ASD and GID, ASD without GID, and GID without ASD. A pediatric gastroenterologist evaluated both GID groups. Parents in all three groups completed questionnaires about their child's behavior and GI symptoms, and a dietary journal. Functional constipation was the most common type of GID in children with ASD (85.0%). Parental report of any GID was highly concordant with a clinical diagnosis of any GID (92.1%). Presence of GID in children with ASD was not associated with distinct dietary habits or medication status. Odds of constipation were associated with younger age, increased social impairment, and lack of expressive language (adjusted odds ratio in nonverbal children: 11.98, 95% confidence interval 2.54–56.57). This study validates parental concerns for GID in children with ASD, as parents were sensitive to the existence, although not necessarily the nature, of GID. The strong association between constipation and language impairment highlights the need for vigilance by health-care providers to detect and treat GID in children with ASD. Medications and diet, commonly thought to contribute to GID in ASD, were not associated with GID status. These findings are consistent with a hypothesis that GID in ASD represents pleiotropic expression of genetic risk factors. En ligne : http://dx.doi.org/10.1002/aur.237 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=155 [article] Gastrointestinal Dysfunction in Autism: Parental Report, Clinical Evaluation, and Associated Factors [Texte imprimé et/ou numérique] / Phillip GORRINDO, Auteur ; Dean C. WILLIAMS, Auteur ; Evon B. LEE, Auteur ; Lynn S. WALKER, Auteur ; Susan G. MCGREW, Auteur ; Pat LEVITT, Auteur . - 2012 . - p.101-108. Langues : Anglais (eng) in Autism Research > 5-2 (April 2012) . - p.101-108 Mots-clés : autism  constipation  diet  functional gastrointestinal disorders  nonverbal communication  social behavior Index. décimale : PER Périodiques Résumé : The objectives of this study were to characterize gastrointestinal dysfunction (GID) in autism spectrum disorder (ASD), to examine parental reports of GID relative to evaluations by pediatric gastroenterologists, and to explore factors associated with GID in ASD. One hundred twenty-one children were recruited into three groups: co-occurring ASD and GID, ASD without GID, and GID without ASD. A pediatric gastroenterologist evaluated both GID groups. Parents in all three groups completed questionnaires about their child's behavior and GI symptoms, and a dietary journal. Functional constipation was the most common type of GID in children with ASD (85.0%). Parental report of any GID was highly concordant with a clinical diagnosis of any GID (92.1%). Presence of GID in children with ASD was not associated with distinct dietary habits or medication status. Odds of constipation were associated with younger age, increased social impairment, and lack of expressive language (adjusted odds ratio in nonverbal children: 11.98, 95% confidence interval 2.54–56.57). This study validates parental concerns for GID in children with ASD, as parents were sensitive to the existence, although not necessarily the nature, of GID. The strong association between constipation and language impairment highlights the need for vigilance by health-care providers to detect and treat GID in children with ASD. Medications and diet, commonly thought to contribute to GID in ASD, were not associated with GID status. These findings are consistent with a hypothesis that GID in ASD represents pleiotropic expression of genetic risk factors. En ligne : http://dx.doi.org/10.1002/aur.237 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=155

Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes / Beth A. MALOW in Journal of Autism and Developmental Disorders, 42-8 (August 2012)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 42-8 (August 2012) . - p.1729-1737 Titre : Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes Type de document : Texte imprimé et/ou numérique Auteurs : Beth A. MALOW, Auteur ; Karen W. ADKINS, Auteur ; Susan G. MCGREW, Auteur ; Lily WANG, Auteur ; Suzanne E. GOLDMAN, Auteur ; Diane FAWKES, Auteur ; Courtney BURNETTE, Auteur Année de publication : 2012 Article en page(s) : p.1729-1737 Langues : Anglais (eng) Mots-clés : Melatonin  Insomnia  Actigraphy  Clinical trial  Children’s sleep habits questionnaire  Child behavior checklist  Autism diagnostic observation schedule Index. décimale : PER Périodiques Résumé : Supplemental melatonin has shown promise in treating sleep onset insomnia in children with autism spectrum disorders (ASD). Twenty-four children, free of psychotropic medications, completed an open-label dose-escalation study to assess dose–response, tolerability, safety, feasibility of collecting actigraphy data, and ability of outcome measures to detect change during a 14-week intervention. Supplemental melatonin improved sleep latency, as measured by actigraphy, in most children at 1 or 3 mg dosages. It was effective in week 1 of treatment, maintained effects over several months, was well tolerated and safe, and showed improvement in sleep, behavior, and parenting stress. Our findings contribute to the growing literature on supplemental melatonin for insomnia in ASD and inform planning for a large randomized trial in this population. En ligne : http://dx.doi.org/10.1007/s10803-011-1418-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=178 [article] Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes [Texte imprimé et/ou numérique] / Beth A. MALOW, Auteur ; Karen W. ADKINS, Auteur ; Susan G. MCGREW, Auteur ; Lily WANG, Auteur ; Suzanne E. GOLDMAN, Auteur ; Diane FAWKES, Auteur ; Courtney BURNETTE, Auteur . - 2012 . - p.1729-1737. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 42-8 (August 2012) . - p.1729-1737 Mots-clés : Melatonin  Insomnia  Actigraphy  Clinical trial  Children’s sleep habits questionnaire  Child behavior checklist  Autism diagnostic observation schedule Index. décimale : PER Périodiques Résumé : Supplemental melatonin has shown promise in treating sleep onset insomnia in children with autism spectrum disorders (ASD). Twenty-four children, free of psychotropic medications, completed an open-label dose-escalation study to assess dose–response, tolerability, safety, feasibility of collecting actigraphy data, and ability of outcome measures to detect change during a 14-week intervention. Supplemental melatonin improved sleep latency, as measured by actigraphy, in most children at 1 or 3 mg dosages. It was effective in week 1 of treatment, maintained effects over several months, was well tolerated and safe, and showed improvement in sleep, behavior, and parenting stress. Our findings contribute to the growing literature on supplemental melatonin for insomnia in ASD and inform planning for a large randomized trial in this population. En ligne : http://dx.doi.org/10.1007/s10803-011-1418-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=178

Sleep is associated with problem behaviors in children and adolescents with Autism Spectrum Disorders / Suzanne E. GOLDMAN in Research in Autism Spectrum Disorders, 5-3 (July-September 2011)  

Permalink

---

1 (1 - 6 / 6)